Brand name: RayStation. Generic name: Treatment Planning System. Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years. RayStation is a software system designed for treatment planning and analysis of radiation therapy. The treatment plans provide treatment unit set-up parameters and estimates of dose distributions expected during the proposed treatment, and may be used to administer treatments after review and approval by the intended user. The system functionality can be configured based on user needs. The intended users of RayStation shall be clinically qualified radiation therapy staff trained in using the system.
Published September 12, 2012 · Recall initiated: May 9, 2012
Summary
FDA records medical device Class II recall Z-2324-2012, published September 12, 2012 and initiated May 9, 2012. Recalling firm: RAYSEARCH LABORATORIES AB; Status: Terminated; Reported quantity: 19 units; Lot: Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
The firm decided to recall when an issue was found with the dose calculation in RayStation 2.5, Raystation 2.5.1. The problem has not caused any patient mistreatment or other incidents. However, the user must be aware of this information to avoid incorrect dose calculations during treatment planning. The dose calculation is not correctly normalized in the unusual case of preventing the optimizatio
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- RAYSEARCH LABORATORIES AB
- Distributor
- Worldwide distribution: USA (nationwide) including states of: FL, MA, NJ, and NY; and countries of: Canada Germany, Netherlands and Switzerland.
- Lot
- Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years.
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- Sweden
Related recalls
- FDARayCare 2024A SP4. Oncology Information Systems.July 8, 2026
- FDARayCare 2024A SP1. Oncology Information Systems.July 8, 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 14.0.0, 15.0.0, 15.1.3 SoftwareJanuary 28, 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 17.0.0, 17.0.1 Software Version:January 28, 2026
- FDAVersaTREK Windows Software, Version 5.4.3 is a component of the VersaTrek System. The Software CD will beSeptember 12, 2012
- FDA100 ft roll of tubing inside a cardboard box. Medical devices are sealed into the tubes prior to ethyleneSeptember 12, 2012
Questions about this recall
Was Brand name: RayStation. Generic name: Treatment Planning System. Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years. RayStation is a software system designed for treatment planning and analysis of radiation therapy. The treatment plans provide treatment unit set-up parameters and estimates of dose distributions expected during the proposed treatment, and may be used to administer treatments after review and approval by the intended user. The system functionality can be configured based on user needs. The intended users of RayStation shall be clinically qualified radiation therapy staff trained in using the system. recalled?
Yes. FDA published recall Z-2324-2012 on September 12, 2012. Reported hazard: The firm decided to recall when an issue was found with the dose calculation in RayStation 2.5, Raystation 2.5.1. The problem has not caused any patient mistreatment or other incidents. However, the user must be aware of this information to avoid incorrect dose calculations during treatment planning. The dose calculation is not correctly normalized in the unusual case of preventing the optimizatio
What should I do if I have this product?
Voluntary: Firm initiated · Letter